



COMPANY ANNOUNCEMENT

23 September 2022

No. 22-2022 – Inside information

ViroGates announces CE-IVD approval for suPARnostic® TurbiLatex on the Beckman Coulter AU5800 platform

BIRKERØD, DENMARK – ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, announces that it has completed the development and regulatory approval (CE-IVD in Europe) of its suPARnostic® TurbiLatex product for the Beckman Coulter AU5800 platform.

Today's announcement means hospitals using the Beckman Coulter instrument platform can, from now on, run suPARnostic® TurbiLatex along with their other biomarkers.

Beckman Coulter Inc. is a diagnostics company based in California. Beckman Coulter is part of the Danaher Corporation headquartered in Washington. The total turnover of Danaher is approx. 30 billion USD.

The Beckman Coulter AU5800 platform is a leading clinical chemistry analyzer that can process around 2,000 samples per hour with a full menu of biomarkers, including biomarkers for therapeutic drug monitoring.

The approval of suPARnostic® TurbiLatex for the AU5800 platform complements the previous approvals for the Abbott Architect and Alinity, the Roche Diagnostics cobas systems, and the Siemens Atellica & ADVIA XPT system.

The suPARnostic® TurbiLatex product is a pivotal element in ViroGates' European expansion strategy focusing on the acute care market

Jakob Knudsen, CEO of ViroGates, says: "We are excited to be able to offer suPARnostic® TurbiLatex on the Beckman Coulter AU5800 platform. We have customers in Spain, Greece and Italy awaiting this approval and we look forward to implementing our products at hospitals using this platform. Beckman Coulter has a strong foothold in many of the markets that ViroGates is currently targeting, especially in the Southern part of Europe. Today's announcement means that suPARnostic® TurbiLatex is now available on platforms from all of the four most prominent players in the clinical chemistry area, Beckman Coulter, Abbott, Siemens and Roche Diagnostics."

The announcement can be found at <https://www.virogates.com/investor/announcements>

For further information, please contact:

ViroGates A/S:

CEO, Jakob Knudsen

Tel. (+45) 2226 1355, email: jk@virogates.com

Certified Advisor:

Västra Hamnen Corporate Finance

Per Lönn

Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se

About ViroGates

ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.

The company was founded in 2000. Headquartered in Denmark, ViroGates' sales force covers the Nordics, Spain, and France, while distributors serve other markets. ViroGates' shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.

About suPAR and suPARnostic®

suPAR is the biomarker detected by ViroGates' suPARnostic® products and is a protein in plasma, measurable in every human being. suPAR is considered a general risk status biomarker indicating disease presence, disease severity and progression, organ damage and mortality risk across disease areas such as cardiovascular diseases, kidney diseases, type 2 diabetes, cancer, etc. Strong scientific evidence from more than 850 clinical trials and studies show that the higher the level of suPAR, the worse the prognosis for the patient.

The suPARnostic® products can be used to support healthcare professionals in making clinical decisions on hospitalization or discharge of acute care patients. The increasing demands on health systems globally and tightening healthcare budgets necessitate efficiency improvements and innovative solutions in hospitals. The use of suPAR in clinical routine in emergency departments can improve patient care and reduce healthcare costs by increasing the number of discharges by up to 34% and reducing the average hospital length-of-stay by up to 6% without affecting mortality. suPARnostic® TurbiLatex is currently available on Roche Diagnostics' cobas® instruments, Siemens Healthineers ADVIA® XPT and Atellica® instruments and the Abbott Labs Architect™ and Alinity™ instruments, and on the Beckman Coulter AU58000 system. ViroGates works with partners to develop solutions for other platforms.